Table 4.
Viruses used in ATAP
| Serotype | Main target receptor | Tumor specificity | Arming | |
|---|---|---|---|---|
| Ad5-D24-GMCSF [92] | 5 | Coxsackie virus and adenovirus receptor | 24 bp deletion in E1A1) | GMCSF |
| Ad5-RGD-D24 [103] | 5 | Alpha-v-beta integrins | 24 bp deletion in E1A1) | No |
| Ad5-RGD-D24-GMCSF [103] | 5 | Alpha-v-beta integrins | 24 bp deletion in E1A1) | GMCSF |
| ICOVIR-7 [104] | 5 | Alpha-v-beta integrins | E2F1 promoter and 24 bp deletion in E1A1) | No |
| Ad5/3-Cox2L-D24 [73] | 5 | Desmoglein-2 | Cox2L promoter and 24 bp deletion in E1A1) | No |
| Ad5/3-D24-GMCSF [88]* | 5 | Desmoglein-2 | 24 bp deletion in E1A1) | GMCSF |
| Ad5/3-hTERT-hCD40L [73] | 5 | Desmoglein-2 | hTERT promoter2) | CD40L |
| Ad5/3-E2F1-D24-GMCSF [105] | 5 | Desmoglein-2 | E2F1 promoter and 24 bp deletion in E1A 1) | GMCSF |
| Ad5/3-D24-hNIS [80] | 5 | Desmoglein-2 | 24 bp deletion in E1A1) | hNIS |
| Ad3-hTERT-E1A [64] | 3 | Desmoglein-2 | hTERT promoter2) | No |
*Ad5/3-D24-GMCSF, also known as CGTG-102, and later renamed ONCOS-102, has been subsequently used in several phase 1 and phase 2 clinical trials (www.targovax.com)
1)Replication in cells with a deficient Rb/p16 pathway (a hallmark of cancer)
2)Replication in cells with active telomerase (a hallmark of cancer)